NCT00591851View on ClinicalTrials.gov

Phase II Study of Dose-Dense Doxurubicin and Cyclophosphamide (AC) Followed By Paclitaxel With Trastuzumab in HER2/ NEU-Amplified Breast Cancer: Feasibility

PHASE2CompletedINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

December 31, 2004

Primary Completion Date

June 30, 2008

Study Completion Date

June 30, 2008

Conditions
Breast Cancer
Interventions
DRUG

AC [Adriamycin (A) (also known as doxorubicin) and Cyclophosphamide (C)] Followed By Paclitaxel (P)

AC \[Adriamycin (A) (also known as doxorubicin) and Cyclophosphamide (C)\] Followed By Paclitaxel (P)

Trial Locations (1)

10065

Memorial Sloan Kettering Cancer Center, New York

Sponsors

Collaborators (2)

Amgen
Genentech, Inc.
All Listed Sponsors
collaborator

Amgen

INDUSTRY

collaborator

Genentech, Inc.

INDUSTRY

lead

Memorial Sloan Kettering Cancer Center

OTHER